+86 137 2013 4139
+86 137 2013 4139
| CAS: | 842133-18-0 | Cat No: | JKN00307 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Product Description
| CAS | 842133-18-0 | Cat No | JKN00307 | |
| Name | Canagliflozin | |||
| Synonyms | JNJ-24831754 | |||
| Smiles | O[C@H]1C(C2=CC=C(C)C(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O | |||
| Chemical Name | (3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol | |||
| Formula | C24H25FO5S | MWt | 444.520 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. In March 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
